focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.95
Bid: 2.90
Ask: 3.00
Change: 0.75 (34.09%)
Spread: 0.10 (3.448%)
Open: 1.90
High: 3.00
Low: 1.90
Prev. Close: 2.20
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Subscription Agreement Update

22 May 2019 07:00

RNS Number : 7643Z
ValiRx PLC
22 May 2019
 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

Subscription Agreement Update

 

London, UK, 22 May 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces an update regarding the second tranche ("Tranche 2") of shares to be issued under the subscription agreement (the "Agreement" or the "Subscription") with European High Growth Opportunities SF (the "Investor") announced on 26 April 2019.

 

Tranche 2

The Company advises that admission of the Tranche 2 subscription shares is now expected to occur on or around 23 May 2019. Admission was initially expected to occur on around 21 May 2019. A further announcement will be made by the Company in due course in relation to Tranche 2.

 

Convertible Funds & Warrants

As previously announced, the Subscription Agreement is part of a wider financing arrangement between the Company and the Investor, which stipulates that the Investor shall provide to the Company additional financing by way of convertible funds with attached warrants ("Convertible Funds" and "Warrants"). Definitive documentation in relation to this is yet to be signed as the Company is required to receive authority at a forthcoming shareholder meeting to enable the Convertible Funds, including the attached Warrants, to be implemented.

The Company wishes to provide further detail regarding two aspects of the Convertible Funds, being the "Make Whole Amount" provision and the "Break Fee".

Make Whole Amount

The first tranche of the Convertible Funds (totalling £500,000), which will be drawn down in the event that definitive documentation is signed, has attached to it a "Make Whole Amount" such that the subscription price for the first tranche of the Convertible Funds shall be reduced in the event that the Company's share price declines in the period to the issuance of this first tranche of the Convertible Funds. This is to be calculated by multiplying the stock performance of the Company (expressed as a percentage) by £1,000,000. The stock performance percentage is based on any decline from a price of 0.52p, being the closing share price of the Company's shares on 19 April 2019.

Break Fee

Should the Company not receive authority from shareholders to issue sufficient shares for the purpose of the Convertible Funds, or should definitive documentation in relation to the Convertible Funds not be signed, in either case before 22 June 2019, ValiRx shall be required to pay the investor a Break Fee totalling £150,000 plus an additional amount in the event the Company's share price declines in the period to the date the Break Fee crystallises. This additional amount is to be calculated by multiplying the stock performance of the Company (expressed as a percentage) by £1,000,000. The stock performance percentage is based on any decline from a price of 0.52p, being the closing share price of the Company's shares on 19 April 2019.

The Company advises that it is commencing discussions with the Investor to amend the basis that is used to calculate the quantum of the Break Fee. The Company does not expect the outcome of these discussions on the quantum of the Break Fee to have an adverse impact on the Company. A further update will be made in due course.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com

 

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray/Jo Turner/Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Novum Securities Limited

Colin Rowbury

Tel: +44 (0) 20 7399 9400

 

 

 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRABMFTMBATBIL
Date   Source Headline
6th Dec 20224:35 pmRNSPrice Monitoring Extension
6th Dec 202212:00 pmRNSShareholder Communications and Investor Webinar
6th Dec 20227:00 amRNSQuarterly Operational and Strategy Update
24th Oct 20227:00 amRNSSubsidiary Launched and IP License Signed
18th Oct 20227:00 amRNSIssue of Share Options
11th Oct 20227:00 amRNSDirector Appointment
30th Sep 20228:47 amRNSHolding(s) in Company
22nd Sep 20227:00 amRNSLive Shareholder Q&A and industry events
8th Sep 20227:00 amRNSAppointment of Interim Chief Scientific Officer
6th Sep 20227:15 amRNSProposed Appointment of Non-Executive Director
6th Sep 20227:00 amRNSIssue of Share Options
31st Aug 20227:00 amRNSHalf-year Report
17th Aug 20227:00 amRNSShareholder Communications
14th Jul 202210:46 amRNSHolding(s) in Company
13th Jul 20222:15 pmRNSSuccessful evaluation of breast cancer programme
7th Jul 202211:07 amRNSDirector/PDMR Shareholding
5th Jul 202211:45 amRNSHolding(s) in Company
5th Jul 20227:00 amRNSBroker Option Results
30th Jun 20223:00 pmRNSResult of AGM and Appointment of Joint Broker
30th Jun 202210:31 amRNSIssue of Equity
30th Jun 202210:30 amRNSExtends exclusivity period for TheoremRx
17th Jun 202210:01 amRNSUpdate on VAL201 sub-license agreement
7th Jun 20224:33 pmRNSAnnual Report, AGM Notice & Director Resignation
23rd Mar 20227:00 amRNSUpdate on proposed sub-license of VAL201
15th Mar 20227:00 amRNSOperational and Strategy Update
14th Feb 20227:00 amRNSEvaluation agreement with University of Barcelona
5th Jan 20224:41 pmRNSSecond Price Monitoring Extn
5th Jan 20224:36 pmRNSPrice Monitoring Extension
5th Jan 20222:06 pmRNSSecond Price Monitoring Extn
5th Jan 20222:00 pmRNSPrice Monitoring Extension
5th Jan 202211:00 amRNSPrice Monitoring Extension
5th Jan 20229:06 amRNSSecond Price Monitoring Extn
5th Jan 20229:00 amRNSPrice Monitoring Extension
5th Jan 20227:16 amRNSSigns Service Agreement with TheoremRx
20th Dec 20217:00 amRNSAmends License for VAL201 with CRT
16th Dec 202110:46 amRNSEvaluation agreement with Hokkaido University
11th Nov 20217:00 amRNSLive Shareholder Q&A and Investor presentations
8th Nov 20213:03 pmRNSHolding(s) in Company
2nd Nov 20217:00 amRNSSigns Letter of Intent to Sub-License VAL201
26th Oct 20212:00 pmRNSPrice Monitoring Extension
26th Oct 202111:05 amRNSSecond Price Monitoring Extn
26th Oct 202111:00 amRNSPrice Monitoring Extension
26th Oct 20217:00 amRNSHolding(s) in Company
20th Oct 20211:19 pmRNSHolding(s) in Company
19th Oct 202112:23 pmRNSHolding(s) in Company
18th Oct 20214:41 pmRNSSecond Price Monitoring Extn
18th Oct 20214:36 pmRNSPrice Monitoring Extension
18th Oct 20212:06 pmRNSSecond Price Monitoring Extn
18th Oct 20212:01 pmRNSPrice Monitoring Extension
18th Oct 202111:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.